NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019
Patrick A. Brown 1 , Matthew Wieduwilt 2 , Aaron Logan 3 , Daniel J. DeAngelo 4 , Eunice S. Wang 5 , Amir Fathi 6 , Ryan D. Cassaday 7 , Mark Litzow 8 , Anjali Advani 9 , Patricia Aoun 10 , Bhavana Bhatnagar 11 , Michael W. Boyer 12 , Teresa Bryan 13 , Patrick W. Burke 14 , Peter F. Coccia 15 , Steven E. Coutre 16 , Nitin Jain 17 , Suzanne Kirby 18 , Arthur Liu 19 , Stephanie Massaro 20 , Ryan J. Mattison 21 , Olalekan Oluwole 22 , Nikolaos Papadantonakis 13 , Jae Park 23 , Jeffrey E. Rubnitz 24 , Geoffrey L. Uy 25 , Kristina M. Gregory 26 , Ndiya Ogba 26 and Bijal Shah 27
Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.
Read Full Article Here: https://doi.org/10.6004/jnccn.2019.0024